These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21737557)

  • 1. Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?
    Bush A; Pedersen S; Hedlin G; Baraldi E; Barbato A; de Benedictis F; Lødrup Carlsen KC; de Jongste J; Piacentini G;
    Eur Respir J; 2011 Oct; 38(4):947-58. PubMed ID: 21737557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Asthma exacerbations: pharmacological prevention].
    Grassin-Delyle S; Girodet PO
    Rev Mal Respir; 2012 Feb; 29(2):232-44. PubMed ID: 22405116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based pharmacologic treatment for mild asthma.
    Koh MS; Irving LB
    Int J Clin Pract; 2007 Aug; 61(8):1375-9. PubMed ID: 17590220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies to reduce asthma exacerbations.
    O'Byrne PM
    J Allergy Clin Immunol; 2011 Aug; 128(2):257-63; quiz 264-5. PubMed ID: 21531015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing safety and efficacy in pediatric asthma management.
    Skoner DP
    Pediatrics; 2002 Feb; 109(2 Suppl):381-92. PubMed ID: 11826254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
    Peters SP; Ferguson G; Deniz Y; Reisner C
    Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing symptoms and exacerbations in pediatric asthma.
    Verberne AA
    Pediatr Pulmonol Suppl; 1997 Sep; 15():46-50. PubMed ID: 9316102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
    Di Stefano F; Cinti B; Antonicelli L
    Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):56-9. PubMed ID: 24702879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological strategies for self-management of asthma exacerbations.
    Reddel HK; Barnes DJ;
    Eur Respir J; 2006 Jul; 28(1):182-99. PubMed ID: 16816348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based asthma management.
    Kallstrom TJ
    Respir Care; 2004 Jul; 49(7):783-92. PubMed ID: 15222910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma.
    Schuh S; Dick PT; Stephens D; Hartley M; Khaikin S; Rodrigues L; Coates AL
    Pediatrics; 2006 Aug; 118(2):644-50. PubMed ID: 16882819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dark side of the moon: severe therapy-resistant asthma in children.
    de Benedictis FM; Carloni I; Bush A
    Monaldi Arch Chest Dis; 2012 Jun; 77(2):83-93. PubMed ID: 23193845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults.
    Rice-McDonald G; Bowler S; Staines G; Mitchell C
    Intern Med J; 2005 Dec; 35(12):693-8. PubMed ID: 16313543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic interventions to reduce the risk of asthma exacerbations.
    O'Byrne PM
    Proc Am Thorac Soc; 2004; 1(2):105-8. PubMed ID: 16113421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED).
    Gappa M; Zachgo W; von Berg A; Kamin W; Stern-Sträter C; Steinkamp G;
    Pediatr Pulmonol; 2009 Nov; 44(11):1132-42. PubMed ID: 19824054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.